[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487939":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":50,"collaborators":52,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":18,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Sophiahemmet University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Periodic CGM- Intervention group","EXPERIMENTAL","The participants in the intervention group will be provided with FreeStyle Libre (Abbott Diabetes Care). Participants wear the sensor and check their glucose level for a period of 28 days (14 days X 2) during week 0-4 and week 10-13.Patient's measurement data from the FreeStyle Libre system will be transferred to the OneTwo Analytics (DDA) analysis tool for an automated analysis and this Insight report will be presented to the participants at visit week 4 (digital) and at visit week 16 (clinical). The diabetes nurse and the patient reviews and discuss trends, patterns, and challenges to support the person's self-management care of their type 2 diabetes. This approach is intended to facilitate communication and patient participation and create the conditions for shared informed decisions and health planning.",[13],"Behavioral: Periodic CGM group with data analysis report- Intervention group",{"label":15,"type":16,"description":17,"interventionNames":18},"Self-monitoring of blood glucose, SMBG and usual care - Control Group","NO_INTERVENTION","The participants in the control group perform SMBG testing as usual including fasting, pre- or post-prandial measurements. They also receive usual care which comprises consultation with physician diabetes specialist or diabetes nurse depending on individual health care needs.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Periodic CGM group with data analysis report- Intervention group","The patients are also instructed to continue to perform SMBG by finger prick if they experience symptoms of hypo- or hyperglycemia. During visit 0 (baseline) the patients is also instructed about how they can log in to the National Diabetes Register (NDR) to access their own NDR's recorded data and use the diabetes questionnaire.",[9],[26],{"name":27,"affiliation":5,"role":28},"Unn-Britt Johansson","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Unn-Britt Johanssson, Professor","CONTACT","+4684062902","unn-britt.johansson@shh.se",[36],{"facility":5,"status":37,"city":38,"state":18,"zip":18,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Stockholm","Sweden","SE",{"type":42,"coordinates":43},"Point",[44,45],18.06871,59.32938,{"lat":45,"lon":44},[48],{"name":49,"role":32,"phone":18,"phoneExt":18,"email":18},"Unn-Britt Johansson, PhD",{"type":28,"investigatorFullName":27,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Principal Investigator, Professor",[53,56,58],{"name":54,"class":55},"Swedish Diabetes Foundation","UNKNOWN",{"name":57,"class":55},"OneTwo Analytics AB",{"name":59,"class":55},"Sophiahemmet","100487939","periodic-continuous-glucose-monitoring-in-patients-with-type-2-diabetes-100487939",false,"NCT05633628","Periodic Continuous Glucose Monitoring in Patients With Type 2 Diabetes","Periodic Continuous Glucose Monitoring to Support a Person-centered Approach During Diabetes Consultations in Patients With Type 2 Diabetes- A Randomised Controlled Study","Inclusion Criteria:\n\n* Adults aged 18-80 years\n* Type 2 diabetes with a duration of \\> 6 months\n* HbA1c 45-70 mmol\u002Fmol\n* Have a smartphone\n* Experience of self-monitoring of blood glucose prior to the study start\n\nExclusion Criteria:\n\n* Prandial insulin\n* Pregnancy or planning pregnancy during the study\n* Breastfeeding\n* Renal disease with estimated glomerular filtration rate (eGFR) \\\u003C45 mL\u002F min\u002F1.73 m2\n* Active malignancy or under investigation for malignancy\n* Severe visual impairment\n* Severe skin allergy that inhibits the use of a continuous glucose monitoring device\n* Glucocorticoids (systemic)\n* Planned or currently using weight reduction medications, programs, or surgery\n* Cognitively or psychologically unable to participate and read instructions\n* Enrolled in other clinical trials\n* Eating disorders","ALL","18 Years","80 Years",{"count":71,"type":72},400,"ESTIMATED","INTERVENTIONAL",[75],"NA","The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.",[78],"Type 2 Diabetes",[80,81],"CGM","Personcentered care","2026-04-23",{"date":84,"type":85},"2026-04-29","ACTUAL",{"date":87,"type":85},"2023-02-01",{"date":89,"type":72},"2026-12",{"name":5,"class":6},1]